Author(s)

Qiren Sun

Corresponding Author

Qiren Sun

ABSTRACT

Chimeric Antigen Receptors (CAR) T cell therapy is a new emerging technique that mainly target B cell lymphoma. It isolates the patients’ own immune cells and uses them to eliminate cancer after receptor engineering. To date, remarkable results have shown its strength and 5 drugs have been approved by U.S. Food and Drug Administration in treating Diffuse Large B-cell lymphoma (DLBCL) and some other subtypes of B cell cancer. Through CAR-T cells are undergoing significantly fast innovation, a series of side effects have occurred. For example, the cytokine releasing syndrome. In addition, as the quick development of CAR, scientists have met some obstacles in the past years and some of them remain troublesome. This review paper focused on the treatment direction of three FDA approved drugs, side effects, current barriers and potential solutions.

KEYWORDS

CAR T therapy, Lymphoma, immunotherapy, cancer